Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trialCELLA, David; HERBST, Roy S; KRIS, Mark G et al.Journal of clinical oncology. 2005, Vol 23, Num 13, pp 2946-2954, issn 0732-183X, 9 p.Article

Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancerSOCINSKI, Mark A; WEISSMAN, Charles; HART, Lowell L et al.Journal of clinical oncology. 2006, Vol 24, Num 30, pp 4840-4847, issn 0732-183X, 8 p.Article

Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomyGOLUBOFF, Erik T; PRAGER, Diane; RUKSTALIS, Daniel et al.The Journal of urology. 2001, Vol 166, Num 3, pp 882-886, issn 0022-5347Conference Paper

TRIBUTA: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerHERBST, Roy S; PRAGER, Diane; RAMIES, David et al.Journal of clinical oncology. 2005, Vol 23, Num 25, pp 5892-5899, issn 0732-183X, 8 p.Article

Efficacy of Gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic Patients with non-small cell lung Cancer a randomized trialKRIS, Mark G; NATALE, Ronald B; ALBAIN, Kathy S et al.JAMA, the journal of the American Medical Association. 2003, Vol 290, Num 16, pp 2149-2158, issn 0098-7484, 10 p.Article

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancerHEYMACH, John V; JOHNSON, Bruce E; KENNEDY, Sarah J et al.Journal of clinical oncology. 2007, Vol 25, Num 27, pp 4270-4277, issn 0732-183X, 8 p.Article

Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinomaDELIOUKINA, Maria L; PRAGER, Diane; PARSON, Mandy et al.Cancer. 2002, Vol 94, Num 8, pp 2174-2179, issn 0008-543XArticle

Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Patients With Chemotherapy-Associated AnemiaSTEENSMA, David P; SLOAN, Jeff A; DAKHIL, Shaker R et al.Journal of clinical oncology. 2011, Vol 29, Num 1, pp 97-105, issn 0732-183X, 9 p.Article